Vizsgálati helyszín
Velocity Clinical Research Germany GmbH
Ahrensburg, 22926, NémetországMég nincs intézményhez kötve
- 14futó vizsgálat
- 10lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 24 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 2. fázis8 vizsgálat
- 3. fázis8 vizsgálat
- 1. fázis4 vizsgálat
- 4. fázis3 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Lezárult10 vizsgálat
- Toboroz7 vizsgálat
- Fut, nem toboroz6 vizsgálat
- Még nem toboroz1 vizsgálat
- Fő szponzor
- AstraZeneca6 vizsgálat
- GlaxoSmithKline3 vizsgálat
- Sanofi3 vizsgálat
- AstraZeneca AB2 vizsgálat
- Boehringer Ingelheim2 vizsgálat
- és még 7
Futó vizsgálatok
Toboroz
Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older
NCT07890454· 3. fázis· Sanofi· Forrás
Toboroz
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07363694· 2/3. fázis· Pfizer· Forrás
Toboroz
Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma
NCT07301736· 2. fázis· Chiesi Farmaceutici S.p.A.· Forrás
Toboroz
A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation
NCT07073950· 4. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Silexan® in mild to moderate major depressive disorder
2025-521744-37-00· 3. fázis· Dr. Willmar Schwabe GmbH & Co. KG· Forrás
Toboroz
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
NCT07177339· 3. fázis· GlaxoSmithKline· Forrás
Toboroz
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
NCT07048262· 2. fázis· CSL Behring· Forrás
Toboroz
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
NCT06959095· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
NCT06154837· 1. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
NCT05846230· 2. fázis· Boehringer Ingelheim· Forrás
Toboroz
Randomized, double-blind, placebo-controlled, multi-centre trial to evaluate the efficacy, safety and tolerability of oral treatment with living bacteria of E. coli DSM 17252 (Symbioflor®2) in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D)
2024-512104-19-00· 4. fázis· SymbioPharm GmbH· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A trial to find the effect of Ginkgo biloba extract EGb 761® and how safe it is in participants with cognitive impairment associated with post COVID-19 syndrome
2024-517199-39-00· 2. fázis· Dr. Willmar Schwabe GmbH & Co. KG· Forrás
Lezárult
Study to Evaluate the Pharmacokinetics and Pharmacodynamics of AZD4604 Given Via the Turbuhaler® Device in Adults With Mild Asthma.
NCT06732882· 1. fázis· AstraZeneca· Forrás
Lezárult
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AZD8630, Administered Once Daily via Inhalation, for 2 Weeks, in Adults with Asthma on Medium-to-high Dose Inhaled Corticosteroids and Long-acting Beta-agonists
2024-514213-35-00· 1. fázis· AstraZeneca AB· Forrás
Lezárult
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
NCT06664619· 3. fázis· Teva Branded Pharmaceutical Products R&D LLC· Forrás
Lezárult
A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations
NCT06529419· 2. fázis· AstraZeneca· Forrás
Lezárult
Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma
NCT06435273· 2. fázis· AstraZeneca· Forrás
Lezárult
A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Selnoflast in Participants with Moderate to Severe Asthma
2023-504304-29-00· 1. fázis· F. Hoffmann-La Roche AG· Forrás
Lezárult
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
NCT06280391· 2. fázis· Sanofi· Forrás
Lezárult
A Study to Evaluate the Effect of BGF MDI, BFF MDI and Placebo MDI on Exercise Parameters in Participants with COPD
2022-502274-16-00· 4. fázis· AstraZeneca AB· Forrás
Lezárult
Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD
NCT05326412· 2. fázis· Sanofi· Forrás
Hibát jelzek